Thalidomide and tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 6, Issue 7, 2002, Pages 569-572

  Fu, Li M ^a,b   Fu Liu, C S ^a  

^a Pac TB/Cancer Res Organization   (United States)

^b NONE   (United States)

Author keywords

Cytokine; Thalidomide; Tuberculosis; Tumor necrosis factor

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUBERCULOSIS; ANIMAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CHILD; CLINICAL TRIAL; IMMUNOLOGY; METABOLISM; MOUSE; RABBIT;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CHILD; CLINICAL TRIALS; CYTOKINES; HUMANS; MICE; RABBITS; THALIDOMIDE; TUBERCULOSIS;

EID: 0036634077     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000; 60: 273-292.
2. Sampaio E P, Sarno E N, Galilly R, Cohn Z A, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
3. Moreira A L, Sampaio E P, Zmuidzinas A, Frindt P, Smith K A, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680.
4. Tavares J L, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw R J. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 1997; 91: 31-39.
5. Klausner J D, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 247-257.
6. Tramontana J M, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1: 384-397.
7. Moreira A L, Tsenova-Berkova L, Wang J, et al. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tuber Lung Dis 1997; 78: 47-55.
8. Schoeman J F, Springer P, Ravenscroft A, et al. Adjunctive thalidomide therapy of childhood tuberculous meningitis: possible anti-inflammatory role. J Child Neurol 2000; 15: 497-503.
9. Tsenova L, Sokol K, Freedman V H, Kaplan G. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 1998; 177: 1563-1572.
10. Bekker L G, Haslett P, Maartens G, Steyn L, Kaplan G. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 2000; 181: 954-965.
11. Gori A, Rossi M C, Marchetti G, et al. Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease. Aids 2000; 14: 1859-1861.
12. Gori A, Rossi M C, Trabattoni D, et al. Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection. J Infect Dis 2000; 182: 639-640.
13. Bala S, Hastings K L, Kazempour K, Inglis S, Dempsey W L. Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex infection in mice. Antimicrob Agents Chemother 1998; 42: 2336-2341.
14. Haslett P A, Corral L G, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885-1892.
15. Tsenova L, Bergtold A, Freedman V H, Young R A, Kaplan G. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci U S A 1999; 96: 5657-5662.
16. Moller D R, Wysocka M, Greenlee B M, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159: 5157-5161.
17. Haslett P A, Klausner J D, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999; 15: 1169-1179.
18. Shannon E J, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 1995; 31: 109-116.
19. Fernandez L P, Schlegel P G, Baker J, Chen Y, Chao N J. Does thalidomide affect IL-2 response and production? Exp Hematol 1995; 23: 978-985.
20. Holland S M. Cytokine therapy of mycobacterial infections. Adv Intern Med 2000; 45: 431-452.
21. Haslett P, Hempstead M, Seidman C, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997; 13: 1047-1054.
22. Daley C L, Small P M, Schecter G F, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326: 231-235.
23. Stenger S, Modlin R L. T cell mediated immunity to Mycobacterium tuberculosis. Curr Opin Microbiol 1999; 2: 89-93.
24. Hashimoto T, Onozaki K, Homma Y, Fukutomi Y, Ichikawa M. Dissociation of protective immunity against tuberculosis and tuberculin hypersensitivity at a level of lymphokines. Dev Biol Stand 1986; 58(Pt B): 553-559.
25. Johnson C M, Cooper A M, Frank A A, Orme I M. Adequate expression of protective immunity in the absence of granuloma formation in Mycobacterium tuberculosis-infected mice with a disruption in the intracellular adhesion molecule 1 gene. Infect Immun 1998; 66: 1666-1670.
26. Flynn J L, Goldstein M M, Triebold K J, Koller B, Bloom B R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 1992; 89: 12013-12017.
27. Rolph M S, Raupach B, Kobernick H H, et al. MHC class Ia-restricted T cells partially account for beta2-microglobulin-dependent resistance to Mycobacterium tuberculosis. Eur J Immunol 2001; 31: 1944-1949.
28. Flynn J L, Ernst J D. Immune responses in tuberculosis. Curr Opin Immunol 2000; 12: 432-436.
29. Haslett P A. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1998; 25 (Suppl 6): 53-57.
30. Schoeman J F, Ravenscroft A, Hartzenberg H B. Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess. Childs Nerv Syst 2001; 17: 370-372.